BRIEF-Spruce Biosciences Announces Topline Results From Cahmelia-204 In Adult CAH And Cahptain-205 In Adult And Pediatric CAH

Reuters12-11

Dec 10 (Reuters) - Spruce Biosciences Inc :

* SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM CAHMELIA-204 IN ADULT CAH AND CAHPTAIN-205 IN ADULT AND PEDIATRIC CAH

* SPRUCE BIOSCIENCES INC - CAHMELIA-204 STUDY DID NOT ACHIEVE PRIMARY ENDPOINT

* SPRUCE BIOSCIENCES INC - EVALUATING STRATEGIC OPPORTUNITIES AND COST-REDUCTION ACTIVITIES

* SPRUCE BIOSCIENCES INC - TO DISCONTINUE CAHMELIA-204 AND CAHPTAIN-205 TRIALS

* SPRUCE BIOSCIENCES INC: WILL BE WINDING DOWN SPRUCE'S INVESTMENT IN TILDACERFONT FOR TREATMENT OF CAH

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490027403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 06:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490027403","market":"us","top_or_hot":-1,"title":"BRIEF-Spruce Biosciences Announces Topline Results From Cahmelia-204 In Adult CAH And Cahptain-205 In Adult And Pediatric CAH","media":"Reuters","content":"<html><body><p>Dec 10 (Reuters) - Spruce Biosciences Inc   :</p><p>   * SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM CAHMELIA-204 IN ADULT CAH AND CAHPTAIN-205 IN ADULT AND PEDIATRIC CAH</p><p>   * SPRUCE BIOSCIENCES INC - CAHMELIA-204 STUDY DID NOT ACHIEVE PRIMARY ENDPOINT</p><p>   * SPRUCE BIOSCIENCES INC - EVALUATING STRATEGIC OPPORTUNITIES AND COST-REDUCTION ACTIVITIES</p><p>   * SPRUCE BIOSCIENCES INC - TO DISCONTINUE CAHMELIA-204 AND CAHPTAIN-205 TRIALS</p><p>   * SPRUCE BIOSCIENCES INC: WILL BE WINDING DOWN SPRUCE'S INVESTMENT IN TILDACERFONT FOR TREATMENT OF CAH</p><p>Source text:   Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Spruce Biosciences Announces Topline Results From Cahmelia-204 In Adult CAH And Cahptain-205 In Adult And Pediatric CAH</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Spruce Biosciences Announces Topline Results From Cahmelia-204 In Adult CAH And Cahptain-205 In Adult And Pediatric CAH\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 06:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 10 (Reuters) - Spruce Biosciences Inc   :   * SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM CAHMELIA-204 IN ADULT CAH AND CAHPTAIN-205 IN ADULT AND PEDIATRIC CAH   * SPRUCE BIOSCIENCES INC - ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128525689.USD","symbol_name":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2490027403","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490027403","pubTimestamp":1733870036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 10  - Spruce Biosciences Inc   :   * SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM CAHMELIA-204 IN ADULT CAH AND CAHPTAIN-205 IN ADULT AND PEDIATRIC CAH   * SPRUCE BIOSCIENCES INC - CAHMELIA-204 STUDY DID NOT ACHIEVE PRIMARY ENDPOINT   * SPRUCE BIOSCIENCES INC - EVALUATING STRATEGIC OPPORTUNITIES AND COST-REDUCTION ACTIVITIES   * SPRUCE BIOSCIENCES INC - TO DISCONTINUE CAHMELIA-204 AND CAHPTAIN-205 TRIALS   * SPRUCE BIOSCIENCES INC: WILL BE WINDING DOWN SPRUCE'S INVESTMENT IN TILDACERFONT FOR TREATMENT OF CAHSource text:   Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4588":"碎股","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4175":"保健护理产品经销商","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","SPRB":"Spruce Biosciences, Inc.","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","BK4585":"ETF&股票定投概念","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4139":"生物科技","CAH":"卡地纳健康","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC"},"translate_title":"简介-Spruce Biosciences宣布Cahmelia-204治疗成人CAH和Cahptain-205治疗成人和儿童CAH的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRB":1,"CAH":1},"content_text":"Dec 10 (Reuters) - Spruce Biosciences Inc   :   * SPRUCE BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM CAHMELIA-204 IN ADULT CAH AND CAHPTAIN-205 IN ADULT AND PEDIATRIC CAH   * SPRUCE BIOSCIENCES INC - CAHMELIA-204 STUDY DID NOT ACHIEVE PRIMARY ENDPOINT   * SPRUCE BIOSCIENCES INC - EVALUATING STRATEGIC OPPORTUNITIES AND COST-REDUCTION ACTIVITIES   * SPRUCE BIOSCIENCES INC - TO DISCONTINUE CAHMELIA-204 AND CAHPTAIN-205 TRIALS   * SPRUCE BIOSCIENCES INC: WILL BE WINDING DOWN SPRUCE'S INVESTMENT IN TILDACERFONT FOR TREATMENT OF CAHSource text:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490027403"}